^
Association details:
| Biomarker: | MLH3 overexpression + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug Class: | CDK4 inhibitor + CDK6 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
2140 / 14 - DNA damage response in circulating tumor cells shows predictive value for metastatic breast cancer patients receiving CDK4/6 inhibitors
Published date:
03/15/2023
Excerpt:
Blood of 90 HR+/HER2-MBC pts drawn before CDK4/6i plus endocrine TX....We identified overexpression of transcripts involved in DNA damage response mechanisms (CETN2, MLH3 and/or PCNA) at baseline to have predictive and/or prognostic value in first line CDK4/6i treated pts.
